Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Apogee Therapeutics Inc (NASDAQ: APGE) was $37.29 for the day, down -2.18% from the previous closing price of $38.12. In other words, the price has decreased by -$2.18 from its previous closing price. On the day, 0.55 million shares were traded. APGE stock price reached its highest trading level at $38.63 during the session, while it also had its lowest trading level at $36.94.
Ratios:
Our analysis of APGE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 16.36 and its Current Ratio is at 16.36. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on July 07, 2025, Reiterated its Buy rating but revised its target price to $115 from $100 previously.
On March 13, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $95.
On November 25, 2024, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $89.Canaccord Genuity initiated its Buy rating on November 25, 2024, with a $89 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 06 ’25 when Dambkowski Carl sold 2,725 shares for $37.78 per share. The transaction valued at 102,950 led to the insider holds 236,273 shares of the business.
Dambkowski Carl sold 10,090 shares of APGE for $454,954 on Jul 02 ’25. The Chief Medical Officer now owns 238,998 shares after completing the transaction at $45.09 per share. On Jul 02 ’25, another insider, CARL DAMBKOWSKI, who serves as the Officer of the company, bought 22,345 shares for $44.26 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APGE now has a Market Capitalization of 2222349824 and an Enterprise Value of 1683989120.
Stock Price History:
The Beta on a monthly basis for APGE is 1.43, which has changed by -0.25479615 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, APGE has reached a high of $63.50, while it has fallen to a 52-week low of $26.20. The 50-Day Moving Average of the stock is -6.49%, while the 200-Day Moving Average is calculated to be -8.84%.
Shares Statistics:
APGE traded an average of 886.11K shares per day over the past three months and 562020 shares per day over the past ten days. A total of 46.10M shares are outstanding, with a floating share count of 37.34M. Insiders hold about 37.35% of the company’s shares, while institutions hold 83.12% stake in the company. Shares short for APGE as of 1753920000 were 8396660 with a Short Ratio of 9.48, compared to 1751241600 on 8663116. Therefore, it implies a Short% of Shares Outstanding of 8396660 and a Short% of Float of 30.659999999999997.
Earnings Estimates
The dynamic stock of Apogee Therapeutics Inc (APGE) is currently being evaluated by a team of 4.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$1.36, with high estimates of -$0.9 and low estimates of -$1.7.
Analysts are recommending an EPS of between -$4.64 and -$4.93 for the fiscal current year, implying an average EPS of -$4.76. EPS for the following year is -$5.26, with 4.0 analysts recommending between -$4.0 and -$6.28.
